TICKERNERD
Menu
BIAFBIAFHealthcare · Diagnostics & Research

BIAF Stock Forecast: bioAffinity Technologies, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$3.56

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 14 Oct 2026 — in the weakest quartile.

Market cap
$4.7M
Ticker Nerd rank
16 / 100
Median analyst target
—
Analysts covering
1
Revenue$1.5M+19.0% y/y
Operating income−$3.3M
Net income−$3.4M
Free cash flow−$3.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

BIAF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores bioAffinity Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
96
Volatility
59
Accruals
52
Growth
45
Momentum
28
Revisions
25
Value
13
Quality
11
Issuance
5

Size (96): Smaller than most of the companies we track.

Issuance (5): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BIAF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BIAF, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
1 Apr 2025Maxim GroupDowngradeHold—
23 July 2024Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BIAF appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

BIAF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

bioAffinity Technologies, Inc. (BIAF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.0×

Cheaper than 76% of US stocks

Price / sales
0.8×

Cheaper than 73% of US stocks

Price / book
0.4×

Cheaper than 85% of US stocks

EV / EBITDA
−0.1×

Cheaper than 62% of US stocks

Growth & margins
Revenue growth (YoY)
19.0%

Higher than 68% of US stocks

Earnings growth (YoY)
19.0%

Higher than 57% of US stocks

Gross margin
28.0%

Higher than 31% of US stocks

Operating margin
−220.8%

Higher than 10% of US stocks

Net margin
−257.3%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−1860.2%

Higher than 1% of US stocks

Return on assets
−125.1%

Higher than 2% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

bioAffinity Technologies, Inc. (BIAF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • bioAffinity Technologies, Inc. has a market value of $4.7M and an enterprise value of $962K.

  • Revenue in the twelve months to 30 June 2026: $5.8M. The latest quarter grew 19.0% year on year.

  • Net income over the same four quarters: −$15.2M, a −259.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$11.6M.

  • Shares outstanding: 452,204.

  • Trailing P/E: −0.0×; forward P/E: −6.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • bioAffinity Technologies, Inc. employs 57 people — $103K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Oct 2026

Data provided by Twelve Data

Peers

BIAF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
BIAFbioAffinity Technologies, Inc.$4.7M
16
NDRAENDRA Life Sciences, Inc.$7.2M
27
XWELXWELL, Inc.$7.3M
35
ISPCiSpecimen, Inc.$2.6M
23
ADVBAdvanced Biomed, Inc.$8.5M
23
PRPOPrecipio, Inc.$39.0M
47
MDXHMDxHealth SA$60.3M
52

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own bioAffinity Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BIAF news & analysis

bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026

Business Wire · 13 Oct 2026positive

bioAffinity Technologies said it will present positive research data at CHEST 2026 on a new test under development to measure lung inflammation in asthma and COPD, as well as drug-related receptors.

Why it matters — The presentation concerns research progress on a test being developed by bioAffinity for asthma- and COPD-related lung inflammation.

WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRNewsWire · 9 Oct 2026neutral

WallachBeth Capital announced that bioAffinity Technologies closed its previously announced registered direct offering of common shares or pre-funded warrants to an institutional investor. The offering was priced at $6.122 per share or $6.115 per pre-funded warrant, at-the-market under Nasdaq rules.

Why it matters — The closing provides BIAF watchers with an update on the company’s registered direct financing.

bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Business Wire · 9 Oct 2026neutral

bioAffinity Technologies announced it closed a $4 million registered direct financing of common stock and a concurrent private placement, priced at-the-market under Nasdaq rules.

Why it matters — The financing adds capital to the company and is relevant to BIAF watchers tracking its fundraising and share issuance.

WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

PRNewsWire · 8 Oct 2026neutral

WallachBeth Capital announced that bioAffinity Technologies entered into a definitive agreement with an institutional investor for a registered direct offering of common stock, or pre-funded warrants in lieu of shares, priced at-the-market under Nasdaq rules. The headline describes the financing as approximately $4 million and notes a concurrent private placement.

Why it matters — The transaction involves issuance of BIAF securities and is relevant to investors tracking the company’s financing activity.

bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

Business Wire · 8 Oct 2026neutral

bioAffinity Technologies announced an approximately $4 million registered direct financing of common stock and a concurrent private placement, priced at-the-market under Nasdaq rules.

Why it matters — The financing may be relevant to BIAF watchers tracking the company’s capital-raising activity and share issuance.

FAQ

Frequently asked questions about BIAF stock

Is BIAF stock a buy right now?

Of the 1 analysts covering bioAffinity Technologies, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks bioAffinity Technologies, Inc. 16 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank BIAF?

As at 14 Oct 2026, bioAffinity Technologies, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (96 of 100).

What is the BIAF stock forecast for 2030?

No analyst covering bioAffinity Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BIAF are extrapolating price history, which says nothing about the business.

What does bioAffinity Technologies, Inc. do?

BioAffinity Technologies Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other diseases of the lung.

What is the latest news on BIAF?

The most recent item we track (Business Wire, 13 Oct 2026): "bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026". bioAffinity Technologies said it will present positive research data at CHEST 2026 on a new test under development to measure lung inflammation in asthma and COPD, as well as drug-related receptors.

Company

About bioAffinity Technologies, Inc.

BioAffinity Technologies Inc. is a biotechnology company focused on noninvasive diagnostics for early-stage lung cancer and other diseases of the lung. Its core offering is CyPath Lung, a laboratory-developed test that uses flow cytometry and automated analysis of sputum samples to identify cell populations associated with cancer. The company operates through two main business segments, Diagnostic Research and Development and Laboratory Services, combining test development with clinical laboratory activity. BioAffinity Technologies also works on targeted cancer therapeutics and other proprietary diagnostic platforms designed to support earlier disease detection and more precise analysis of biological samples. Based in San Antonio, Texas, BioAffinity Technologies serves the health technology and medical diagnostics market with products aimed at improving lung disease detection and diagnostic workflows.

CEO Ms. Maria Zannes J.D. · 57 employees · United States · https://bioaffinitytech.com